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Myogenesis is the developmental program that generates and regenerates skeletal muscle. This process is impaired in patients afflicted
with myotonic dystrophy type 1 (DM1). Muscle development is disrupted in infants born with congenital DM1, and recent evidence suggests
that defective regeneration may contribute to muscle weakness and wasting in affected adults. DM1 represents the first example of a human
disease that is caused, at least in part, by pathogenic mRNA. Cell culture models have been used to demonstrate that mutant DM1 mRNA
takes on a gain-of-function and inhibits myoblast differentiation. Although the molecular mechanism(s) by which this mutant mRNA disrupts
myogenesis is not fully understood, recent findings suggest that anomalous RNA–protein interactions have downstream consequences that
compromise key myogenic factors. In this review, we revisit morphological studies that revealed the nature of myogenic abnormalities seen
in patients, describe cell culture systems that have been used to investigate this phenotype and discuss recent discoveries that for the first time
have identified myogenic events that are disrupted in DM1.
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Skeletal myogenesis is a tightly regulated developmental
program that directs myoblasts (muscle precursor cells) to
differentiate into muscle fibers. During this process—which
occurs in an embryo to make muscle and in an adult to
replace lost muscle—myoblasts are stimulated to initiate
differentiation-specific genes, withdraw from the cell cycle
and fuse together to form syncitial myotubes that are
ultimately organized into myofibers (see Fig. 1). Later,
fibers mature into one of several different fiber types
(reviewed in Scott et al., 2001). Growth of skeletal muscle
is mediated by satellite cells (considered muscle stem cells)
that fuse with growing fibers (Seale and Rudnicki, 2000). In
adult tissue, satellite cells coordinate muscle regeneration to
repair muscle damage. Activated by muscle stress or dam-
age, satellite cells produce a population of biochemically0012-1606/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: mahadevan@virginia.edu (M.S. Mahadevan).distinct myoblasts that first proliferate and then differentiate
to form new myotubes that are incorporated into damaged
myofibers (Seale and Rudnicki, 2000; see Fig. 1B). On the
molecular level, both embryonic and regenerative myogenic
pathways are governed by the basic helix-loop-helix myo-
genic regulatory transcription factors (MRFs) MyoD, Myf5,
myogenin and MRF4 (reviewed in Sabourin and Rudnicki,
2000). Genetic studies in mice have shown that MyoD and
Myf5 are involved in the commitment of cells to the
myogenic lineage (i.e., becoming myoblasts), whereas myo-
genin and MRF4 are required for myoblast differentiation
(see Fig. 1).
Myotonic dystrophy, or Dystrophia myotonica, type 1
(DM1) is a common form of muscular dystrophy (for review
see Mankodi and Thornton, 2002). DM1, like other mus-
cular dystrophies, is characterized by muscle weakness and
wasting, but is set apart by additional defects in muscle
differentiation. Fetal muscle development is affected in
patients with a congenital form of the disease, and muscle
regeneration may be compromised in adult patients. Here,
we review clinical evidence of myogenic defects in DM1
and discuss recent advances in our understanding of these
defects with cell culture models. An emerging model
Fig. 1. Myogenic differentiation pathways of embryonic, regenerative and C2C12 myoblasts. (A) MyoD and Myf5 are expressed in muscle precursor cells
(myoblasts). These cells proliferate (represented by the round arrow) and in some cases migrate to sites of muscle formation. Myogenin and MRF4 are involved
in the differentiation of myoblasts into multinucleated myotubes that eventually incorporate into myofibers. (B) In adult muscle, satellite cells serve to
regenerate lost tissue. Satellite ‘stem’ cells are normally quiescent, but become activated by muscle damage. Activated satellite cells divide to renew themselves
and produce a lineage of distinct myoblasts. These myoblasts express MyoD or Myf5 and undergo several rounds of mitosis. It has been shown in mice that
MyoD is required for regenerative myoblasts to differentiate. MyoD+ cells initiate differentiation-specific genes (such as myogenin and MRF4), exit the cell
cycle and form myotubes that fuse with damaged myofibers. (C) C2C12 myoblasts, isolated from injured adult mouse muscle (i.e., activated satellite cells),
express both MyoD and Myf5 and proliferate when cultured in growth media. When growth factors are removed, differentiation genes (such as myogenin and
p21) are induced, and the cells withdraw from the cell cycle and fuse into myotubes.
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that alter the expression or activity of factors involved in
regulating the myogenic pathway.Myotonic dystrophy
Common features of adult-onset DM1 include myotonia
(delayed muscle relaxation after a voluntary contraction),
progressive skeletal muscle loss, cardiac conduction ab-
normalities and insulin resistance (Harper, 1989). Congen-
ital DM1 (CDM1), which affects patients from birth, is
more severe. CDM1 patients initially show a different
spectrum of symptoms including hypotonia, mental retar-dation and, the focus of this review, impaired muscle
development (Harper, 1989). There is a 25% neonatal
mortality rate, and survivors go on to develop the adult
form of DM1 in their teenage years. Inheritance of DM1 is
autosomal dominant. The DM1 mutation, which is associ-
ated with all congenital cases and 98% of cases overall, is
a trinucleotide (CTG) repeat expansion in a serine–threo-
nine protein kinase gene named DM protein kinase
(DMPK) (Brook et al., 1992; Fu et al., 1992; Mahadevan
et al., 1992). There is a general correlation between repeat
number and disease severity, and CDM patients usually
inherit over a thousand repeats (Harley et al., 1993; Hunter
et al., 1992). Several human diseases are caused by
expanded triplet repeats (reviewed in Cummings and
Fig. 2. Mutant DMPK mRNA. Mutant DMPK transcripts accumulate in ribonuclear inclusions (red) in the nuclei (blue) of myoblasts from a DM1 patient (B)
but not unaffected myoblasts (A). (C) Similar nuclear inclusions form in a C2C12 myoblast model engineered to express lacZ reporter transcripts that contain a
mutant (CUG)200 DMPK 3V-UTR (Amack et al., 1999). Ribonuclear inclusions are detected by RNA FISH (fluorescent in situ hybridization). Images: J. D.
Amack. (D) Wild-type DMPK transcripts contain 5–37 CUG repeats in the 3V-UTR. (E) Mutant mRNA contains hundreds to thousands of CUG repeats. The
proximal region (239 nucleotides) and the distal region (484 nucleotides) of the 3V-UTR are indicated.
J.D. Amack, M.S.Mahadevan / Developmental Biology 265 (2004) 294–301296Zoghbi, 2000). Many of these mutations alter protein-
coding sequences and create gain-of-function mutant pro-
teins. The DM1 mutation, however, is in the 3V-untrans-
lated region (3V-UTR) of DMPK, and therefore does not
affect the protein-coding sequence. Several different mech-
anisms have been proposed to explain how this mutation
causes disease (reviewed in Tapscott, 2000), but accumu-
lating data suggest that mutant DMPK mRNA molecules
containing expanded CUG repeats play a role in many
DM1 phenotypes (Amack et al., 1999; Charlet et al., 2002;
Mankodi et al., 2000, 2002; Savkur et al., 2001). Mutant
DMPK mRNA, which is expressed in all affected tissues,
aggregates into nuclear inclusions as a full-length, pro-
cessed and polyadenylated transcript (Davis et al., 1997;
Taneja et al., 1995; see Figs. 2B–C), and is thought to
trigger dominant effects by interacting with (and altering
the function of) RNA binding proteins. Recently, a second
mutation (DM2) was identified in patients with DM-like
symptoms that lack a repeat expansion at the DM1 locus.
The DM2 mutation is a noncoding CCTG repeat expan-
sion in the first intron of the zinc finger protein 9 (ZNF9)
gene (Liquori et al., 2001). The ZNF9 mRNA also
accumulates in nuclear inclusions, suggesting that both
mutant ZNF9 and DMPK transcripts cause disease by a
similar gain-of-function mechanism. While the adult DM1
and DM2 phenotypes are similar, congenital cases and
muscle development defects have not been reported in
DM2.Impaired muscle development in DM1
A series of morphologic and histochemical studies con-
ducted in the 1970s and 1980s revealed muscle develop-
ment defects in neonatal CDM1 patients. Analyzing muscle
biopsies from four CDM1 cases, Sarnat and Silbert (1976)
found that each muscle sample showed signs of immaturity.
These included small muscle fibers, ranging from 5 to 10 A
(15 A is normal), centrally located nuclei and an abnormally
large population of satellite cells. The number of satellite
cells normally decreases over the course of muscle devel-
opment, reflecting the incorporation of these cells into
myofibers. Histochemical methods used to determine mus-
cle fiber type indicated poor differentiation in CDM1
samples, and often could not distinguish between type I
and type II fibers. Blood vessels and small nerves appeared
normal and there was no indication of inflammation, muscle
fiber splitting, necrosis or degeneration. In another study,
Sahgal et al. (1983) found that the muscle was also
underdeveloped in preterm CDM1 infants. Muscle from
patients delivered at 27, 34 and 37 weeks of gestation
showed numerous small myotubes and an increased per-
centage of satellite cells. Myotubes, which are rare in an
unaffected fetus after the 22nd week, were prominent in a
patient at 27 weeks, and fibers from patients at 34 and 37
weeks resembled normal muscle at about 24 weeks old.
Consistent with Sarnat and Silbert (1976), histochemical
fiber type differentiation was not observed in the patients at
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(1988) found immature skeletal muscle in four additional
CDM1 cases. In contrast to previous findings, some muscles
were necrotic. The authors proposed that necrosis may result
from degeneration of immature muscle innervated by nor-
mal motoneurons. In one case, successive biopsies (taken at
the ages of 6 months and 3 years) demonstrated that muscle
maturity improves over time but never becomes normal.
Collectively, these studies established that muscle develop-
ment is affected in CDM1 patients and is either delayed or
arrested.
More recently, myoblasts isolated from DM1 patients
were studied using cell culture assays. Satellite cells derived
from quadriceps muscles from three CDM1 fetuses (34.5,
28 and 37 weeks old; each inherited approximately 2300repeats) displayed behavior that corresponds to the aberrant
muscle phenotype observed clinically (Furling et al., 2001).
First, the percentage of CDM1 myoblasts that fused into
myotubes was significantly reduced relative to control
myoblasts. Second, the morphology of the myotubes that
did form in CDM1 cultures was abnormal. These myotubes
were smaller and contained fewer nuclei per myotube.
Third, analysis of myosin heavy chain (MHC) protein
isoforms showed immaturity in CDM1 myotubes. Control
myotubes co-expressed four different MHC isoforms (em-
bryonic, fetal, fast and slow), whereas CDM1 myotubes
showed variable expression patterns and primarily ex-
pressed the embryonic isoform. Another group found con-
sistent differentiation defects in myoblasts isolated from two
additional DM1 patients (1000 repeats and 500 repeats)
(Timchenko et al., 2001). Thus, in vitro studies have
corroborated observations of muscle development defects
in patient biopsies.Cell culture and animal models
Cell culture systems have been used effectively to
investigate how and why myogenesis goes awry in DM1
patients. A number of groups have taken advantage of the
disease-relevant C2C12 myoblast cell line. C2C12 myo-
blasts were originally isolated from injured adult mouse
muscle, and provide an excellent system to study myo-
genesis (Blau et al., 1983; Yaffe and Saxel, 1977). When
cultured in differentiation media that lacks growth factors,
C2C12 cells enter the myogenic differentiation pathway and
fuse into multinucleated myotubes (see Fig. 1C). DMPK
mRNA is expressed in both human myoblasts and C2C12
cells during proliferation and up-regulated during the dif-Fig. 3. Myogenic events disrupted in DM1. This diagram combines
molecular events (1–5) that are compromised in differentiating myoblasts
isolated from DM1 patients or C2C12 myoblasts that express mutant
DMPK 3V-UTR RNA. (A) Normal events in wild-type myoblasts. (1)
MTMR1 pre-mRNA is alternatively spliced to generate a muscle-specific
isoform. (2) MyoD protein is expressed before and throughout differ-
entiation. MyoD translocates to the nucleus to act as a transcription factor
and also physically interacts with CDK4 to inhibit cell proliferation by
inducing cell cycle arrest. (3) MyoD heterodimerizes with E-proteins to
directly transactivate genes required to initiate myogenic differentiation,
such as myogenin. (4) In the cytoplasm, CUGBP1 induces translation of
p21 mRNA. Increased p21 protein levels inhibit CDKs to stop cell
proliferation. (5) Wild-type DMPK mRNA is transported out of the nucleus
and accumulates in the cytoplasm. (B) Aberrant myogenic events in DM1
myoblasts. (1) MTMR1 mRNA splicing is skewed such that the muscle-
specific isoform is not produced. (2) MyoD protein levels are severely
reduced. (3) Compromised MyoD levels are not sufficient to properly
activate differentiation genes. (4) CUGBP1 is mis-localized in the nucleus
leading to reduced p21 translation and cell cycle defects as well as mRNA
splicing defects. (5) Mutant DMPK mRNA aggregates into nuclear
inclusions (red knot). RNA binding factors, such as muscleblind family
members, localize to these inclusions. Such aberrant localization of RNA
binding proteins may be involved in loss of MyoD protein expression or
mis-regulation of RNA splicing events such as MTMR1 mRNA splicing.
N = nucleus, C = cytoplasm.
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expression of wild-type human (Sabourin et al., 1997) and
mouse (Okoli et al., 1998) DMPK cDNAs inhibited C2C12
myoblast differentiation. Using a series of deletion con-
structs, Sabourin et al. (1997) went on to show that this
effect was due to overexpression of the mRNA (DMPK
protein was not required), and that the inhibitory activity
mapped to a conserved 239 nucleotide region in the DMPK
3V-UTR that lies just proximal to the CUG repeat tract (see
Fig. 2E).
In an independent C2C12 cell culture model, heterolo-
gous RNAs have been used to show that reporter transcripts
(lacZ or GFP) containing an expanded CUG tract aggregate
into nuclear inclusions similar to those seen in DM1 patient
cells (see Fig. 2C), and that mutant (CUG)200 DMPK 3V-
UTR RNA reversibly disrupts C2C12 myoblast differenti-
ation (Amack et al., 1999). When the Cre-loxP system was
used to silence expression of the mutant RNA, the myo-
blasts regained the ability to differentiate into myotubes.
This demonstrated that the myogenic defect was dependent
on the expression of mutant 3V-UTR RNA. Characterization
of a spontaneous reversion event that rescued cells express-
ing the mutant DMPK 3V-UTR RNA from the differentiation
defect revealed a deletion that removed sequences distal to
the repeat tract and reduced the number of CUG repeats
from approximately 200 to 5. The RNA produced in these
cells expressed the proximal region of the DMPK 3V-UTR,
arguing against a role of this region in isolation. Further-
more, the results suggested that the deleted RNA sequences,
the distal region or the CUG repeats may mediate the mutant
myogenic phenotype. In a separate study, it was tested
whether these sequences were sufficient to block C2C12
differentiation (Amack and Mahadevan, 2001). RNA con-
taining the CUG tract alone or in combination with the distal
region aggregated into the nuclear inclusions, but, perhaps
surprisingly, did not affect myogenesis. This indicated that
the formation of ribonuclear inclusions is separable from the
differentiation defect and that additional DMPK 3V-UTR
sequences (likely a full-length mutant DMPK 3V-UTR) are
required to block C2C12 differentiation.
The muscle differentiation defect caused by mutant
DMPK 3V-UTR transcripts in cell culture may reflect devel-
opmental abnormalities seen in newborn CDM1 patients or
point to an impaired regenerative capacity of satellite cells
in adult DM patients. Recently, it has come to light that
although many of the same regulatory factors are involved,
there are differences between embryonic myogenesis and
the differentiation program used during muscle regeneration
(Megeney et al., 1996). C2C12 cells were isolated from
adult muscle, so it is likely that these cells more accurately
model regenerative myogenesis. The mutant phenotype seen
in DM1 C2C12 models (e.g., reduced myotube formation) is
similar to what has been observed in cultured DM1 satellite
cells, which provides evidence that satellite cell function is
affected in patients (Furling et al., 2001; Timchenko et al.,
2001). Satellite cells are responsible for replacing lostmuscle, so dysfunction could contribute to muscle weakness
and wasting in DM1. Data regarding regeneration in DM1
muscle are sparse, but it has been noted that there is a
reduced regenerative response to muscle wasting in DM
patients as compared to patients with other forms of mus-
cular dystrophy (Harper, 1989). Although myogenic defects
have not thus far been associated with DM2, trans-dominant
effects of mutant ZNF9 mRNA may potentially contribute
to muscle wasting in adult DM2 patients. The established
cell culture systems described here provide the means to
further investigate regeneration defects in DM.
To date, mouse models have not reproduced the muscle
development defects seen in CDM1. Neither loss-of-func-
tion nor overexpression of DMPK in mice has resulted in
muscle development abnormalities (Jansen et al., 1996;
Reddy et al., 1996). Transgenic mice engineered to over-
express chimeric a-skeletal actin transcripts containing
approximately 250 CUG repeats in the 3V-UTR show nuclear
RNA inclusions and develop DM-like myopathy and myo-
tonic discharges, providing strong evidence for the involve-
ment of mutant RNA containing CUG repeats in DM1
pathology (Mankodi et al., 2000). Interestingly, these mice
do not show signs of muscle developmental defects or
wasting. This is consistent with the hypothesis that DMPK
3V-UTR sequences in addition to the CUG repeats are
required to disrupt myogenesis (perhaps both embryonic
and regenerative). A different mouse model expresses
mutant DMPK transcripts (approximately 300 CUGs) from
a 45 kb genomic DM1 locus transgene (Seznec et al., 2001).
There is no report of muscle developmental defects, but
analysis of adult muscle revealed immature fibers express-
ing neonatal MHC. The authors conclude these fibers to be
active sites of muscle regeneration. The immature fibers
may have simply been ‘caught’ during the maturation
process, or, alternatively, may represent failed regeneration
that has arrested in an intermediate state. The later possi-
bility re-enforces the importance of determining the effects
of mutant DMPK mRNA on regenerative myogenesis.How does mutant RNA disrupt myogenesis?
Molecular studies have begun to uncover how mutant
DMPK mRNA causes disease. A growing body of evidence
suggests that pleiotropic effects of aberrant interactions
between mutant DMPK transcripts and RNA-binding pro-
teins alter the metabolism of ‘target’ mRNAs. Several
factors involved in mRNA processing bind DMPK 3V-
UTR RNA (Lu et al., 1999; Miller et al., 2000; Tian et
al., 2000; Timchenko et al., 1996; Tiscornia and Mahade-
van, 2000). Of these, only members of the muscleblind
family of proteins (MBNL, MBXL, MBLL) have been
shown to colocalize with the ribonuclear inclusions (Fardaei
et al., 2002). The function of these proteins is unknown, but
interestingly, in Drosophila, the absence of muscleblind
leads to eye degeneration and defects in terminal muscle
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repeat binding protein 1 (CUGBP1), does not colocalize
with the mutant DMPK mRNA inclusions (Fardaei et al.,
2002), but it has been suggested that its phosphorylation and
nuclear localization are altered in DM1 cells. CUGBP1 has
been implicated in mRNA splicing and translation defects in
DM1 patients (Charlet et al., 2002; Philips et al., 1998;
Savkur et al., 2001; Timchenko et al., 2001). Expression of
incorrect (misspliced) protein isoforms from two target
mRNAs, the insulin receptor (Savkur et al., 2001) and a
muscle-specific chloride channel (CLC-1) (Charlet et al.,
2002; Mankodi et al., 2002), likely contributes to DM1
insulin resistance and myotonia, respectively. Recent data
suggest that mutant DMPK mRNA disrupts myogenesis in a
similar manner via alteration of critical myogenic factors.
Significant advances have been made in identifying
myogenic factors and events that are targeted in DM1 (see
Fig. 3). Recently, it was discovered that DM1 patient
myoblasts fail to permanently withdraw from the cell cycle
when stimulated to differentiate (Timchenko et al., 2001).
DM1 cells were unable to initiate events that mediate cell
cycle arrest, including induction of the cyclin dependent
kinase (CDK) inhibitor p21, down-regulation of CDK4
activity and formation of Rb/E2F complexes. CUGBP1,
which normally accumulates in the cytoplasm of differenti-
ating myoblasts, was found to be mis-localized in the nuclei
of DM1 myoblasts. Further experiments showed that
CUGBP1 binds p21 mRNA and induces its translation.
Thus, the nuclear localization of CUGBP1 may explain
why p21 mRNA is not properly translated and DM cells fail
to exit the cell cycle.
Another recently reported target is MTMR1 (myotubu-
ularin-related 1) mRNA alternative splicing (Buj-Bello et
al., 2002). MTMR1 is a member of a large family of
phosphatases similar to myotubularin (MTM1), which is
mutated in the muscular disorder X-linked myotubular
myopathy (Laporte et al., 2001). Buj-Bello et al. (2002)
have demonstrated that MTMR1 mRNA is alternatively
spliced to produce a predominant muscle-specific isoform
during normal differentiation of both human and C2C12
myoblasts, and that this splicing event is disrupted specif-
ically in CDM1 myoblasts (>1800 CTG repeats) (see Fig.
3). Although a role for muscle-specific MTMR1 remains to
be established, it is interesting to note that loss of MTM1
results in a congenital disease with symptoms similar to
those seen in CDM1. These include hypotonia, muscle
weakness and muscle fibers that contain central nuclei and
resemble fetal myotubes (Wallgren-Pettersson et al., 1995).
One could speculate that aberrant mRNA splicing that
results in the loss of muscle-specific MTMR1 activity
may contribute to myogenic defects in CDM1.
Using the C2C12 myoblast model system described
above, MyoD has been identified as target of mutant DMPK
3V-UTR RNA (Amack et al., 2002). Northern blot analysis
of myogenic markers indicated that mutant (CUG200) 3V-
UTR transcripts do not affect expression of MyoD or Myf5mRNA, but do dampen the programmed up-regulation of
myogenin and p21 (Amack and Mahadevan, 2001). This
suggests that mutant 3V-UTR RNA acts before the expres-
sion of myogenin in the differentiation pathway (see Fig. 1).
Western blotting and luciferase reporter assays revealed that
expression of mutant DMPK 3V-UTR RNA severely reduced
MyoD (but not Myf5) protein levels and transactivational
activity at time points when MyoD is thought to activate
differentiation genes (Amack et al., 2002). The compro-
mised levels of MyoD likely explain why C2C12 myoblasts
expressing the mutant 3V-UTR RNA fail to initiate the
differentiation program. Supporting this conclusion, increas-
ing MyoD, either spontaneously or by retroviral delivery,
was sufficient to rescue the differentiation defect. Although
it is unclear how MyoD is compromised, mutant DMPK
transcripts could abate MyoD protein production by affect-
ing factors that regulate MyoD mRNA splicing or transla-
tion. Alternatively, mutant transcripts may alter intracellular
cascades that regulate MyoD degradation, which is signaled
by a phosphorylation event carried out by CDK1 and CDK2
(Kitzmann et al., 1999; Song et al., 1998). Importantly,
Timchenko et al. (2001) used MyoD as a readout for
differentiation efficiency and showed that MyoD levels are
also reduced in DM1 patient myoblasts. An attractive model
tying these observations together is that the mutant DMPK
RNA-mediated reduction of MyoD underlies myoblast
dysfunction in DM1.
The deleterious effect of mutant DMPK mRNA on
MyoD protein levels may be connected to multiple molec-
ular aspects of DM1. It is likely that the reduction of MyoD
plays a role in the inability of DM1 cells to efficiently
withdraw from the cell cycle. A 15 amino acid domain of
MyoD, which lacks transactivation capability, facilitates exit
from the cell cycle by directly binding and inhibiting CDK4
(Zhang et al., 1999). One would predict that a loss of MyoD
would adversely affect this aspect of cell cycle arrest. In
support of this, it has been reported that CDK4 activity is
not properly checked in DM1 myoblasts (Timchenko et al.,
2001). There may also be a connection between MyoD and
mRNA splicing defects in DM1 cells. MyoD has been
shown to play a role in muscle-specific alternative splicing
during myogenesis (Ichida et al., 1998). This has lead us to
speculate that the splicing defects found in DM1 muscle
cells (i.e., InR, CLC-1, MTMR1) may be interrelated to the
effects we have observed in our C2C12 cell culture system.
Specifically, reduced MyoD levels in cells expressing the
mutant DMPK 3V-UTR RNA may contribute to missplicing
of specific transcripts during myogenic differentiation.Conclusion
Myotonic dystrophy, first described in 1909 (Steinert,
1909), has been studied for nearly a century. DM1 presents a
complex clinical picture that affects multiple body systems
and there is no precedent for how the DM1 untranslated
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phenotypes. Despite these challenges, great strides have
been made towards understanding the basis of this disease.
Clinical studies have carefully described numerous abnor-
malities seen in DM1 patients, including myogenic defects
in CDM1 infants, allowing researchers to deconstruct DM
and investigate the causes of specific aspects individually.
Here, we have considered the progress made towards
determining how muscle development is impaired in DM1.
Clinicians, who recognized that muscle development was
abnormal in CDM1 patients, analyzed biopsies and revealed
that affected muscle fibers were small, immature and
showed an increased number of satellite cells. These find-
ings pointed to a disruption in the myogenic program.
Subsequent isolation and culture of DM1 muscle cells have
shown that myogenic defects are likely due to myoblast
dysfunction. Differentiation of DM1 myoblasts is greatly
diminished, and DM1 muscle cell cultures reflect pheno-
types seen in vivo. A significant breakthrough came when
mutant DMPK mRNA sequences were shown to inhibit
C2C12 myoblast differentiation. This was the first evidence
that expression of mutant mRNA was sufficient to cause a
DM1 phenotype. A working model proposes that mutant
DMPK transcripts, known to interact with several RNA
binding proteins, alter the metabolism (splicing, transport,
translation, degradation) of specific target mRNAs that
regulate myoblast function (see Fig. 3). Since myoblasts
play essential roles in both the growth of developing muscle
and the repair of adult muscle, compromised myoblasts may
explain muscle development defects in CDM1 and contrib-
ute to muscle degeneration in adult DM1 patients.
Although important advances have been made, a big
question still remains. How exactly does mutant DMPK
mRNA cause these effects? A growing list of RNA-binding
proteins including members of the MBNL family (Fardaei et
al., 2002), the CELF family of proteins (Ladd et al., 2001),
PKR (Tian et al., 2000) and several other RNA splicing
factors (Tiscornia and Mahadevan, 2000) has been shown to
interact with the DMPK 3VUTR mRNA. In the future, there
may be additional RNA-binding proteins posited for DM1
pathogenesis. Many of these proteins are quite similar in
structure (e.g., MBNL or CELF family members) and
putative function. Which of these proteins is relevant to
DM? Is there only one or are many of them involved? These
RNA-binding proteins have various isoforms and exhibit
varying tissue and developmental expression. Given the
pleiotropic nature of DM and variable age of onset, it may
well be that several proteins could be relevant and account
for the various tissue specific and developmental features of
DM. Over the past few years, cell culture and animal models
of DM1 have been generated that recapitulate clinical and
molecular features found in DM1 patients and their cells. In
addition, many molecular targets such as MyoD, insulin
receptor, CLC-1 and MTMR1 have been identified and can
be used as ‘‘molecular readouts’’ to enable a feasible
experimental approach to studying the molecular pathogen-esis of DM. Through the study of such diverse targets, and
using various models, a convergence on the relevant inter-
actions and signaling pathways may be forthcoming and
provide new insights into RNA signaling and cell growth
and differentiation.Acknowledgments
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